Innovative Wound Healing Technology: Corryn Biotechnologies Secures $1.3 Million in Funding

Corryn Biotechnologies is thrilled to announce the successful raising of $1.3 million in funding to accelerate its pioneering development of innovative wound care technology. Our company is on the forefront of revolutionizing wound management through our advanced biomimetic nano- and micro-fibrous wound dressings, which are designed to be fabricated and deposited directly onto wound sites at the point of care. This groundbreaking approach addresses the significant limitations of current commercial wound dressings, namely their insufficient regenerative properties. What sets our solution apart is our proprietary tech stack, including an in-house developed handheld applicator that utilizes sealed sterile cartridges containing unique material formulations. These formulations are transformed into fibrous substrates via a cutting-edge electrospinning process, delivering a painless and effective treatment to patients in real-time. With the new funding, Corryn Biotechnologies aims to enhance the capabilities of our applicator, expand our material platform options, and conduct critical clinical testing to validate the efficacy of our dressings. This infusion of capital not only propels us forward in our quest to improve patient outcomes, but it also aligns with our mission to bring state-of-the-art regenerative medicine to a broader audience. We are immensely grateful for the support of our investors and excited about the future as we continue to innovate and lead in the biotechnological landscape of wound care.